

Anthrax - Pipeline Insight, 2021

<https://marketpublishers.com/r/A67BECA46A6EN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: A67BECA46A6EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Anthrax - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anthrax pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Anthrax Understanding

Anthrax: Overview

Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as *Bacillus anthracis*. Anthrax can be found naturally in soil and commonly affects domestic and wild animals around the world. Although it is rare in the United States, people can get sick with anthrax if they come in contact with infected animals or contaminated animal products. Anthrax can cause severe illness in both humans and animals.

'Anthrax - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anthrax pipeline landscape is provided which includes the disease overview and Anthrax treatment guidelines. The assessment part of the report embraces, in depth

Anthrax commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anthrax collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Anthrax R&D. The therapies under development are focused on novel approaches to treat/improve Anthrax.

Anthrax Emerging Drugs Chapters

This segment of the Anthrax report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anthrax Emerging Drugs

AV 7909: Emergent BioSolutions

The vaccine candidate AV7909 is being developed for post-exposure prophylaxis of disease resulting from suspected or confirmed *Bacillus anthracis* exposure, in conjunction with the recommended course of antimicrobial therapy. AV7909 is comprised of Anthrax Vaccine Adsorbed (AVA) in combination with an adjuvant. Several Phase 1 and Phase 2 clinical studies have investigated the safety, efficacy, and stability profile of AV7909. The lot consistency, safety, and immunogenicity of AV7909 are currently being evaluated in a Phase 3 trial.

BW 1010: BlueWillow Biologics

BW-1010 is the company's next-generation intranasal anthrax vaccine candidate. The vaccine is currently under phase 1 of clinical trials.

Further product details are provided in the report

Anthrax: Therapeutic Assessment

This segment of the report provides insights about the different Anthrax drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Anthrax

There are approx. 10+ key companies which are developing the therapies for Anthrax. The companies which have their Anthrax drug candidates in the most advanced stage, i.e. phase III include, Emergent BioSolutions.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Anthrax pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anthrax: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anthrax therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anthrax drugs.

Anthrax Report Insights

Anthrax Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Anthrax Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Anthrax drugs?

How many Anthrax drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anthrax?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anthrax therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Anthrax and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Emergent BioSolutions

BlueWillow Biologics

Planet Biotechnology

Altimune

GC Pharma

Crestone Inc

Greffex

Hawaii Biotech

Integrated BioTherapeutics

Q BioMed

VLP Biotech

Porton Biopharma

Aphios

DEINOVE

ENESI Pharma

Paratek Pharmaceuticals

Fab'entech

SporeGen

Key Products

AV 7909

BW 1010

PBI 220

NasoShield

GC-1109

Research programme: DNA vaccines

Ba-ISTAb

MAN 04

DNV3837

Nuzyra

Contents

Introduction

Executive Summary

Anthrax: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Anthrax – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Anthrax companies' collaborations, Licensing, Acquisition -Deal Value Trends

Anthrax Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

AV 7909: Emergent BioSolutions

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

BW 1010: BlueWillow Biologics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Anthrax Key Companies

Anthrax Key Products

Anthrax- Unmet Needs

Anthrax- Market Drivers and Barriers

Anthrax- Future Perspectives and Conclusion

Anthrax Analyst Views

Anthrax Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Anthrax

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Anthrax

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Anthrax - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/A67BECA46A6EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A67BECA46A6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970